Cargando…
Primary Patient-Derived Cancer Cells and Their Potential for Personalized Cancer Patient Care
Personalized cancer therapy is based on a patient’s tumor lineage, histopathology, expression analyses, and/or tumor DNA or RNA analysis. Here, we aim to develop an in vitro functional assay of a patient’s living cancer cells that could complement these approaches. We present methods for developing...
Autores principales: | Kodack, David P., Farago, Anna F., Dastur, Anahita, Held, Matthew A., Dardaei, Leila, Friboulet, Luc, von Flotow, Friedrich, Damon, Leah J., Lee, Dana, Parks, Melissa, Dicecca, Richard, Greenberg, Max, Kattermann, Krystina E., Riley, Amanda K., Fintelmann, Florian J., Rizzo, Coleen, Piotrowska, Zofia, Shaw, Alice T., Gainor, Justin F., Sequist, Lecia V., Niederst, Matthew J., Engelman, Jeffrey A., Benes, Cyril H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cell Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5745232/ https://www.ncbi.nlm.nih.gov/pubmed/29241554 http://dx.doi.org/10.1016/j.celrep.2017.11.051 |
Ejemplares similares
-
Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant
non-small cell lung cancer
por: Raoof, Sana, et al.
Publicado: (2019) -
Clinicopathologic Characteristics and Outcomes for Patients With KRAS G12D-Mutant NSCLC
por: Cooper, Alissa J., et al.
Publicado: (2022) -
Safety and Success of Repeat Lung Needle Biopsies in Patients with Epidermal Growth Factor Receptor‐Mutant Lung Cancer
por: Fintelmann, Florian J., et al.
Publicado: (2019) -
Diffuse Lung Metastases in EGFR-Mutant Non-Small Cell Lung Cancer
por: Digumarthy, Subba R., et al.
Publicado: (2019) -
Acquired Resistance of EGFR-Mutated Lung Cancer to Tyrosine Kinase Inhibitor Treatment Promotes PARP Inhibitor Sensitivity
por: Marcar, Lynnette, et al.
Publicado: (2019)